PFE — Pfizer Inc.
Healthcare · ETF XLV · as of 2026-09-21
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Pfizer Inc.
NYQ
Healthcare · Pharmaceuticals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...
Price & today
$27.74
ATR(14) 0.50 (1.80%)
| Stock today | +0.29% |
| Sector ETF today | +0.37% |
| Residual (stock-specific) | -0.08% |
Sector correlation
| 20-day correlation with XLV | 0.66 |
| 60-day correlation with XLV | 0.73 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $27.75 |
| 20 EMA | $27.70 |
| 50 EMA | $27.04 |
| EMA stack | BULLISH |
| RSI(14) | 53.4 |
| 52-week high distance | -3.51% |
| 52-week low distance | +26.26% |
Signals
| Market F&G | 45.6 |
| Bull% | 12.2% |
| OVTLYR status | SELL (11d) |
| Sector rank | #522 |
| Next earnings | 2026-11-02 (TNS, 42d) |
MarketSmith metrics - our compute
RS Rating
69.0
ADR%
1.6
RMV (tight)
5.0
Ext (ATR>20EMA)
0.1
Rel Vol
77.0%
U/D 50d
1.60
U/D 25d
1.36
Accum/Dist 25d
2 / 1
EPS YoY
-1.0%
LoD dist
42.0
Off 52w High
5.0%
Above 52w Low
17.6%
1W / 1M
+0.1 / -0.2
Avg $Vol 50d
998.1M
Mkt Cap (B)
158.1
Trend 8/8
no
Leads Group
YES
Sector XLV
+0.8% 1W
Base len (VCP)
10wk (4/6)
Coil (base shape)
85TVPX COIL
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
20.4
Fwd P/E
9.9
PEG
13.8
Price/Book
1.7
Profit margin
12.4%
ROE
8.9%
Debt/Equity
78.0
Rev growth
-1.2%
Analyst target
$29 (+5%)
Analyst rating
BUY
Institutional %
69.0%
Insider %
0.1%
Float %
99.6%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
79 / 146
Industry
Pharmaceuticals
Float
5.68B
Float turnover 20d
0.6%
Avg $Vol 20d / 50d
941.1M / 998.1M
Days to cover
3.5
Short % float
2.4%
Institutional %
69.0%
Weinstein stage
3
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Oct-24 | 1.06 | - | 17,702.0 | +31% |
| Feb-25 | 0.63 | +530% | 17,763.0 | +22% |
| Apr-25 | 0.92 | +12% | 13,715.0 | -8% |
| Aug-25 | 0.78 | +30% | 14,653.0 | +10% |
| Nov-25 | 0.87 | -18% | 16,654.0 | -6% |
| Feb-26 | 0.66 | +5% | 17,557.0 | -1% |
| May-26 | 0.75 | -18% | 14,451.0 | +5% |
| Aug-26 | 0.77 | -1% | 15,034.0 | +3% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 20 · Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder The Motley Fool
- Sep 18 + 3 Dividend Stocks to Buy and Hold for 10 Years The Motley Fool
- Sep 18 − 2 High-Yield Dividend Stocks to Buy and 1 to Avoid The Motley Fool
- Sep 18 · If a Recession Is Coming, History Says This 1 No-Brainer ETF Is the Smartest Buy Right Now The Motley Fool
- Sep 17 + Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape GlobeNewswire Inc.
- Sep 15 · Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID? Zacks Investment Research
- Sep 15 + 4 Prostate Cancer Drug Stocks to Watch During Awareness Month Zacks Investment Research
- Sep 15 + Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities GlobeNewswire Inc.